How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,743 results for

Herpes Zoster

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Varicella Zoster Virus glycoprotein E antigen (Shingrix) - Herpes Zoster

Varicella Zoster Virus glycoprotein E antigen (Shingrix) - Herpes Zoster 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 25 January 2018 EMA/88588/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report Shingrix International non-proprietary name: herpes zoster vaccine (recombinant, adjuvanted) Procedure (...) GMT Geometric Mean Titre GSK GlaxoSmithKline HCP Host Cell Protein HCT Haematopoietic stem Cell Transplant HI Haemagglutinin Inhibition HIV Human Immunodeficiency Virus HP Hydrogen Peroxide HZ Herpes Zoster HZO HZ Ophthalmicus Assessment report EMA/88588/2018 Page 5/170 HZ/su The herpes zoster subunit candidate vaccine (50 µg gE/AS01 B ), also called gE/AS01 B candidate vaccine IC Immunocompromised ICH International Conference on Harmonization IDMC Independent Data Monitoring Committee IFN

2018 European Medicines Agency - EPARs

3. Herpes zoster infection

Herpes zoster infection Herpes zoster infection - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Herpes zoster infection Last reviewed: February 2019 Last updated: July 2018 Summary Typically presents with pain described as burning or stabbing, followed by a vesicular rash in the affected dermatome; location of symptoms depends on the affected nerve. Diagnosis is primarily based on the typical clinical symptoms (...) , such as dermatomal pain and eruption of grouped vesicles in the same dermatome. Confirmation can be done using polymerase chain reaction (PCR) methods. Treatment is primarily to reduce pain using analgesics and viral replication using antiviral medicine such as aciclovir. Antiviral therapy may reduce the severity of postherpetic neuralgia. Early antiviral therapy is particularly important in ophthalmic zoster and zoster in the immunocompromised. Definition Herpes zoster (HZ), caused by reactivation of varicella

2018 BMJ Best Practice

4. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial. (PubMed)

Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial. Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantation zoster.To assess the efficacy and adverse event profile of the recombinant zoster vaccine in immunocompromised (...) primary end point was occurrence of confirmed herpes zoster cases.Among 1846 autologous HSCT recipients (mean age, 55 years; 688 [37%] women) who received 1 vaccine or placebo dose, 1735 (94%) received a second dose and 1366 (74%) completed the study. During the 21-month median follow-up, at least 1 herpes zoster episode was confirmed in 49 vaccine and 135 placebo recipients (incidence, 30 and 94 per 1000 person-years, respectively), an incidence rate ratio (IRR) of 0.32 (95% CI, 0.22-0.44; P < .001

2019 JAMA Controlled trial quality: predicted high

5. Shingrix vaccine for herpes zoster

Shingrix vaccine for herpes zoster Systematic Review Report: Efficacy and safety of adjuvanted herpes zoster subunit vaccine Drug Assessment Working Group October 2018 2 Table of Contents Page number Abbreviations/Glossary 3 Executive summary 4-6 Introduction 7-8 Research Question: PICOS format 8-9 Methods 9-11 Results Search findings Risk of bias in included studies Outcomes 1. HZ vaccine vs Placebo 2. HZ subunit vaccine versus live attenuated OKA-strain VZV vaccine 3. HZ subunit vaccine (...) Diagnoses Decisions (via PCR, HZAC) Appendix 6: HZ Incidence by Subgroup: Pooled data from ZOE-50 and ZOE-70 31-47 31-33 34 35-44 45 46 47 3 Abbreviations/Glossary AE: adverse event Anti-gE: anti-glycoprotein E ARR: absolute risk reduction AUC: area under the curve CD4: Cluster of differentiation 4 CSR: Clinical Study Report ELISA: Enzyme-linked Immunosorbent Assay EQ-5D: Euro-Quality of Life - 5 Dimension GSK: GlaxoSmithKline HZ: herpes zoster HZAC: Herpes Zoster Ascertainment Committee IM

2018 Therapeutics Letter

6. Herpes zoster ophthalmicus

Herpes zoster ophthalmicus Herpes Zoster Ophthalmicus (HZO) submit The College submit You're here: Herpes Zoster Ophthalmicus (HZO) Herpes Zoster Ophthalmicus (HZO) The CMGs are guidelines on the diagnosis and management of a range of common and rare, but important, eye conditions that present with varying frequency in primary and first contact care. Share options Please login to view the images or . Aetiology Varicella zoster virus (VZV), also known as human herpesvirus-3 (HHV- 3) previous (...) systemic infection (varicella, i.e. chickenpox) virus lies dormant (sometimes for decades) in dorsal root and cranial nerve sensory ganglia reactivation leads to herpes zoster (shingles) herpes zoster ophthalmicus (HZO) is defined by zoster involvement in the ophthalmic division of the trigeminal nerve herpes zoster affects 20-30% of the population at some point in their lifetime; 10-20% of these will develop HZO through involvement of the ophthalmic division of the trigeminal nerve. This represents

2018 College of Optometrists

7. Valacyclovir versus acyclovir for the treatment of herpes zoster ophthalmicus in immunocompetent patients. (PubMed)

Valacyclovir versus acyclovir for the treatment of herpes zoster ophthalmicus in immunocompetent patients. Herpes zoster ophthalmicus affects the eye and vision, and is caused by the reactivation of the varicella zoster virus in the distribution of the first division of the trigeminal nerve. An aggressive management of acute herpes zoster ophthalmicus with systemic antiviral medication is generally recommended as the standard first-line treatment for herpes zoster ophthalmicus infections. Both (...) acyclovir and its prodrug valacyclovir are medications that are approved for the systemic treatment of herpes zoster. Although it is known that valacyclovir has an improved bioavailability and steadier plasma concentration, it is currently unclear as to whether this leads to better treatment results and less ocular complications.To assess the effects of valacyclovir versus acyclovir for the systemic antiviral treatment of herpes zoster ophthalmicus in immunocompetent patients.We searched CENTRAL (which

Full Text available with Trip Pro

2016 Cochrane

8. Vaccines for preventing herpes zoster in older adults. (PubMed)

Vaccines for preventing herpes zoster in older adults. Herpes zoster, also known as 'shingles', is a neurocutaneous disease characterised by the reactivation of the latent varicella zoster virus (VZV), the virus that causes chickenpox when immunity to VZV declines. It is an extremely painful condition that can last many weeks or months and it can significantly compromise the quality of life of affected individuals. The natural process of aging is associated with a reduction in cellular immunity (...) and this predisposes older people to herpes zoster. Vaccination with an attenuated form of VZV activates specific T cell production avoiding viral reactivation. The Food and Drug Administration has approved a herpes zoster vaccine with an attenuated active virus for clinical use among older adults, which has been tested in large populations. A new adjuvanted recombinant VZV subunit zoster vaccine has also been tested. It consists of recombinant VZV glycoprotein E and a liposome-based AS01B adjuvant system

Full Text available with Trip Pro

2016 Cochrane

9. Herpes Zoster Infection and Herpes Zoster Vaccination in a Population-Based Sample of Persons With IBD: Is There Still an Unmet Need? (PubMed)

Herpes Zoster Infection and Herpes Zoster Vaccination in a Population-Based Sample of Persons With IBD: Is There Still an Unmet Need? We aimed to report the rates of herpes zoster infection (HZI) before and after the introduction of herpes zoster vaccine (HZVac) and to determine the rates of HZVac after it became available in Manitoba in 2009.We used the population-based University of Manitoba IBD Epidemiology Database to identify cases of inflammatory bowel disease (IBD) and controls (1984

2018 Inflammatory Bowel Diseases

10. The Epidemiology of Herpes Zoster in the United States During the Era of Varicella and Herpes Zoster Vaccines: Changing Patterns Among Older Adults. (PubMed)

The Epidemiology of Herpes Zoster in the United States During the Era of Varicella and Herpes Zoster Vaccines: Changing Patterns Among Older Adults. Historic herpes zoster incidence trends in US adults have been hard to interpret. Using administrative databases, we extended previous descriptions of these trends through 2016. We observed an age-specific transition, with ongoing increases among younger adults but deceleration in older adults. The patterns are not readily explained.

Full Text available with Trip Pro

2018 Clinical Infectious Diseases

11. The Epidemiology of Herpes Zoster in the United States During the Era of Varicella and Herpes Zoster Vaccines: Changing Patterns Among Children. (PubMed)

The Epidemiology of Herpes Zoster in the United States During the Era of Varicella and Herpes Zoster Vaccines: Changing Patterns Among Children. Varicella vaccination can have complex direct and indirect influences on the epidemiology of herpes zoster among children. We evaluated pediatric herpes zoster trends using administrative databases. Incidence declined in a step-wise pattern since the varicella vaccination program was introduced, suggesting that rates may eventually decline

Full Text available with Trip Pro

2018 Clinical Infectious Diseases

12. The impact of childhood varicella vaccination on the incidence of herpes zoster in the general population: modelling the effect of exogenous and endogenous varicella-zoster virus immunity boosting. (PubMed)

The impact of childhood varicella vaccination on the incidence of herpes zoster in the general population: modelling the effect of exogenous and endogenous varicella-zoster virus immunity boosting. A controversy exists about the potential effect of childhood varicella vaccination on Herpes Zoster (HZ) incidence. Mathematical models projected temporary HZ incidence increase after vaccine introduction that was not confirmed by real-world evidence. These models assume that absence of contacts (...) with infected children would prevent exogenous boosting of Varicella-Zoster-Virus (VZV) immunity and they do not include an endogenous VZV immunity-boosting mechanism following asymptomatic VZV reactivation. This study aims to explore the effect of various assumptions on exogenous and endogenous VZV immunity-boosting on HZ incidence in the general population after introduction of routine childhood varicella vaccination.An age-structured dynamic transmission model was adapted and fitted to the seroprevalence

Full Text available with Trip Pro

2019 BMC Infectious Diseases

13. Evaluation of Varicella-zoster virus-specific cell-mediated immunity by interferon-γ Enzyme-Linked Immunosorbent Assay in adults ≥50 years of age administered a herpes zoster vaccine. (PubMed)

Evaluation of Varicella-zoster virus-specific cell-mediated immunity by interferon-γ Enzyme-Linked Immunosorbent Assay in adults ≥50 years of age administered a herpes zoster vaccine. Varicella-zoster virus (VZV)-specific cell-mediated immunity (CMI) is critical for preventing and controlling the onset of herpes zoster (HZ). To assess VZV CMI, an interferon-γ (IFN-γ) enzyme-linked immunosorbent assay (ELISA) was validated by examining the influence of VZV-specific antigen content, incubation

2019 Journal of medical virology Controlled trial quality: uncertain

14. [Evaluation of gene amplification for diagnosis Herpesviridae infections (cytomegalovirus, herpes simplex virus and varicella-zoster) in people living with HIV]

[Evaluation of gene amplification for diagnosis Herpesviridae infections (cytomegalovirus, herpes simplex virus and varicella-zoster) in people living with HIV] Evaluation de l'amplification génique pour le diagnostic des infections à Herpesviridae (cytomégalovirus, virus herpès simplex et varicelle-zona) chez les personnes vivant avec le VIH [Evaluation of gene amplification for diagnosis Herpesviridae infections (cytomegalovirus, herpes simplex virus and varicella-zoster) in people living (...) with HIV] Evaluation de l'amplification génique pour le diagnostic des infections à Herpesviridae (cytomégalovirus, virus herpès simplex et varicelle-zona) chez les personnes vivant avec le VIH [Evaluation of gene amplification for diagnosis Herpesviridae infections (cytomegalovirus, herpes simplex virus and varicella-zoster) in people living with HIV] Haute Autorité de santé Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation

2016 Health Technology Assessment (HTA) Database.

15. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations. (PubMed)

A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations. The U.S. Advisory Committee on Immunization Practices recently developed recommendations for use of a new recombinant zoster vaccine (RZV).To evaluate the cost-effectiveness of vaccination with RZV compared with zoster vaccine live (ZVL) and no vaccination, the cost-effectiveness of vaccination with RZV for persons who have previously received ZVL (...) with no vaccination, ICERs ranged by age from $10 000 to $47 000 per quality-adjusted life-year (QALY), using a societal perspective and assuming 100% completion of the 2-dose RZV regimen. For persons aged 60 years or older, ICERs were less than $60 000 per QALY. Vaccination with ZVL was dominated by vaccination with RZV for all age groups 60 years or older.Results were most sensitive to changes in vaccine effectiveness, duration of protection, herpes zoster incidence, and probability of postherpetic neuralgia

2019 Annals of Internal Medicine

16. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine. (PubMed)

Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine. Protection against herpes zoster (HZ) induced by the live attenuated zoster vaccine Zostavax (ZVL) wanes within 3-7 years. Revaccination may renew protection. We assessed whether (re)vaccination with the adjuvanted HZ subunit vaccine candidate (HZ/su) induced comparable immune responses in previous ZVL recipients and ZVL-naive individuals

Full Text available with Trip Pro

2017 Journal of Infectious Diseases

17. Herpes Zoster and Recurrent Herpes Zoster (PubMed)

Herpes Zoster and Recurrent Herpes Zoster The incidence of recurrent herpes zoster (HZ) and the relationship between initial and recurrent HZ are not clear.The Miyazaki Dermatologist Society has surveyed ~5000 patients with HZ annually since 1997. A questionnaire regarding HZ and its recurrence was completed by the dermatologists.A total of 34 877 patients with HZ were registered at 43 clinics between June 2009 and November 2015. Among 16 784 patients seen at 10 of the 43 clinics, 1076 patients (...) (6.41%) experienced recurrence. Herpes zoster was more frequent in female than in male patients (5.27 vs 4.25 in 1000 person-years, P < .001), as was HZ recurrence (7.63% vs 4.73%, P < .001). Two and three recurrences were observed in 49 and 3 patients, respectively. Recurrence in the same dermatome was observed in 16.3% of patients, and more frequently this occurred in the left side (P = .027). The number of HZ-experienced persons increased with age, and one third of the population had experienced

Full Text available with Trip Pro

2017 Open forum infectious diseases

18. Evaluation of gene amplification for the diagnosis of Herpesviridae infections (cytomegalovirus, herpes simplex virus and varicella-zoster virus) in people living with HIV

Evaluation of gene amplification for the diagnosis of Herpesviridae infections (cytomegalovirus, herpes simplex virus and varicella-zoster virus) in people living with HIV Evaluation of gene amplification for the diagnosis of Herpesviridae infections (cytomegalovirus, herpes simplex virus and varicella-zoster virus) in people living with HIV - INAHTA Brief

2016 Haute Autorite de sante

19. Optimal gender-specific age for cost-effective vaccination with adjuvanted herpes zoster subunit vaccine in Chinese adults. (PubMed)

Optimal gender-specific age for cost-effective vaccination with adjuvanted herpes zoster subunit vaccine in Chinese adults. Adjuvanted herpes zoster (HZ) subunit (HZ/su) vaccine is recommended for healthy adults aged ≥50 years, yet vaccine efficacy is expected to wane over time. Age-sex specific cost-effectiveness analyses of HZ/su vaccine are warranted to inform decision-making on vaccine policy. We aimed to determine the optimal gender-specific age for cost-effective HZ/su vaccination in Hong

Full Text available with Trip Pro

2019 PLoS ONE

20. Herpes zoster ophthalmicus: Pre-eruption phase sine herpete (PubMed)

Herpes zoster ophthalmicus: Pre-eruption phase sine herpete 29552667 2018 11 14 2451-9936 10 2018 Jun American journal of ophthalmology case reports Am J Ophthalmol Case Rep Herpes zoster ophthalmicus: Pre-eruption phase sine herpete. 201-202 10.1016/j.ajoc.2018.03.004 Sigireddi Rohini R RR Department of Ophthalmology, Baylor College of Medicine, Houston, TX, United States. Lyons Lance J LJ Department of Ophthalmology & Visual Sciences, University of Texas Medical Branch, Galveston, TX, United (...) Journal Article 2018 03 08 United States Am J Ophthalmol Case Rep 101679941 2451-9936 Giant cell arteritis Herpes zoster ophthalmicus Temporal pain Vesicular rash 2018 01 03 2018 02 26 2018 03 05 2018 3 20 6 0 2018 3 20 6 0 2018 3 20 6 1 epublish 29552667 10.1016/j.ajoc.2018.03.004 S2451-9936(17)30394-8 PMC5854874 Clin Exp Ophthalmol. 2005 Dec;33(6):636-8 16402958 J Infect. 2013 Nov;67(5):463-9 23872209 Clin Exp Dermatol. 1997 Nov;22(6):274-6 9604453

Full Text available with Trip Pro

2018 American journal of ophthalmology case reports

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>